122P - Practice patterns and treatment outcomes of molecular tumour board (MTB)-based personalized cancer therapies: A single-center experience

Background

Interdisciplinary Molecular Tumor Boards (MTB) are increasingly implemented to account for the growing complexity in molecular oncology, yet data on MTB practice patterns and patient benefit are heterogeneous. Our aim was to determine local practice patterns and treatment response data of MTB-directed therapies.

Methods

In this retrospective cohort study, consecutive patients referred to the MTB of the Medical University of Graz from 2021-2023 were included. Patients were referred with either existing molecular profiles, or additional genomic sequencing from tissue/liquid biopsies and/or immunohistochemistry was performed. Treatment recommendations were based on ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT) levels. Preliminary treatment response outcomes were disease control rate (DCR), overall response rate (ORR) and duration of response (DOR).

Results

Overall, 249 patients referred to the MTB Graz were included, including external referrals from regional and national centres (18%). The median time from referral to MTB recommendation was 26 days. The most frequent cancer types were breast- (n=69), pancreatic- (n=42), colorectal- (n=24), and non-small cell lung cancer (n=24). Molecular profiling was performed in 88.8% of referred patients (n=221). An actionable alteration was identified in 115 patients (46.2%), comprising ESCAT level I recommendations in 33%, level II in 21% and level III in 45%. MTB-recommended treatment was so far initiated in 57 patients (23%). Common reasons for not implementing treatment was clinical deterioration (n=25) and ongoing previous therapies (n=22). The DCR in treated patients was 45% and ORR was 19%. In the subgroup of patients with ESCAT level I-II recommendations, DCR was 58% and ORR was 29%. Sustained treatment responses (i.e., >12 months DOR) were observed in 12% of treated patients.

Conclusions

A substantial rate of targetable alterations was detected in patients referred to the MTB. Promising treatment response patterns were observed in a subset of patients treated with MTB-recommended therapies. Additional detailed genomic analyses of included patients and treatment response evaluations can be presented at the meeting.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.